http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102898449-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c7c582c58ebb902c3111171ec32c641
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02
filingDate 2012-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7d751088e178b972afc0e88abe3a8d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15eac2b2e4aad5e83523f35756f58603
publicationDate 2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102898449-A
titleOfInvention A kind of method of synthetic crizotinib intermediate
abstract The present invention belongs to the technical field of drug synthesis, and specifically relates to a method for synthesizing an intermediate of Crizotinib . ) as raw material, react with 4- nitropyrazole to prepare compound 3 ; b ) use hydrazine hydrate to reduce the nitro group to obtain amino compound 4 ; In the presence of benzoyl oxide , react with boronate compound 5 to prepare Crizotinib intermediate ( 1 ). Compared with the existing synthetic method, the inventive method has the following advantages: use the diazotization method to synthesize the boric acid ester product, compared with the existing method, that is, the Pd- catalyzed Miyaura boronation method, this method avoids the use of expensive palladium Catalyst and ligand, and has the advantages of mild reaction conditions, high yield, simple operation, cheap and easy to obtain raw materials, short reaction cycle, etc., and is very easy for industrialized large-scale production.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017197604-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111285890-A
priorityDate 2012-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011100502-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011136247-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102584795-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468088670
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467283456
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16770068
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467582510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419730877

Total number of triples: 21.